

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED

銘源醫療發展有限公司*

(Incorporated in Bermuda with limited liability)

(Stock code: 0233)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board of Directors (the “**Board**”) of Mingyuan Medicare Development Company Limited (the “**Company**”) announces that Dr. WONG, Peter Kai-hong (“**Dr. Wong**”) has been appointed as a Non-executive Director of the Company with effect from 1 December 2017.

Dr. Wong Peter Kai-hong, aged 67, is currently a practicing clinical and academic neurologist in Vancouver, Canada. He obtained his Bachelor of Engineering Physics and Doctor of Medicine degrees from McMaster University, Hamilton, Canada, followed by post-graduate specialty training in neurology and neurophysiology at the University of California and Harvard University, before joining Children’s Hospital, Vancouver where he is currently. Dr. Wong is also Professor of neurology in the medical school of UBC, Canada, Honorary Professor at Shanghai Medical College of Fudan University and Jichi Medical University, Honorary Member of the Japan Society of Brain Electromagnetic Topography, and Founding Editor of the Brain Topography, an international journal. As UBC Coordinator of International Affair, he had been involved in international medical liaison with China, HK, Japan and other countries. Dr. Wong has knowledge and experience with medical instrumentation and their clinical applications.

Dr. Wong has not held any directorship in publicly listed companies, whether in Hong Kong or overseas, during the last three years. He does not have any relationship with any other Directors, senior management or substantial or controlling shareholders of the Company. As at the date of this announcement, he does not have any interest in shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong. Pursuant to the Company’s New Bye-laws, Dr. Wong will hold office until the next annual general meeting of the Company when he will be eligible for re-election. His appointment shall then be subject to retirement by rotation and re-election at general meetings of the Company in accordance with the Company’s New Bye-laws.

** For identification purpose only*

The Director's fee of Dr. Wong as a Non-executive Director of the Company under his appointment letter is HK\$120,000 per annum (subject to review by the Board from time to time).

Save as disclosed herein, there are no other matters concerning Dr. Wong's appointment as a Non-executive Director that need to be brought to the attention of the shareholders of the Company nor any information to be disclosed pursuant to the requirements of Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Company welcomes Dr. Wong for his joining and his wealth of experience in medical area will be of immense value and be most beneficial to the Company.

By Order of the Board
Mingyuan Medicare Development Company Limited
LAM Ping Cheung
Chairman

Hong Kong, 1 December 2017

As at the date of this announcement, the Board comprises (i) Mr. Lam Ping Cheung and Mr. Hui Yip Wing as executive Directors; (ii) Ms. Chan Mee Sze, Mr. Lam Suk Ping, Mr. Cheung Chi Ming and Ms. Fan Stephanie Winnie as independent non-executive Directors.